{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:35:49Z","timestamp":1776742549219,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Child Adolesc Psychiatry Ment Health"],"DOI":"10.1186\/s13034-026-01069-6","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:14:23Z","timestamp":1773386063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The renaissance of research on psychedelics in child and adolescent psychopharmacology"],"prefix":"10.1186","volume":"20","author":[{"given":"Marc-Antoine","family":"Crocq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Auby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"1069_CR1","doi-asserted-by":"publisher","unstructured":"psychedelic (adj.), sense 2.b, Oxford English Dictionary, September. 2025, https:\/\/doi.org\/10.1093\/OED\/6159164580","DOI":"10.1093\/OED\/6159164580"},{"key":"1069_CR2","unstructured":"Codignola Agnese. LSD. Da Albert Hofmann a Steve Jobs, da Timothy Leary a Robin Carhart-Harris: Storia di una sostanza stupefacente. 2019, UTET Editori, Torino, Italia. 270 pp. The contacts between Osmond and Huxley are described in Chap. 3."},{"key":"1069_CR3","doi-asserted-by":"publisher","first-page":"863088","DOI":"10.3389\/fpsyt.2022.863088","volume":"13","author":"DE Nichols","year":"2022","unstructured":"Nichols DE, Entactogens. How the Name for a Novel Class of Psychoactive Agents Originated. Front Psychiatry. 2022;13:863088. https:\/\/doi.org\/10.3389\/fpsyt.2022.863088.","journal-title":"Front Psychiatry"},{"key":"1069_CR4","doi-asserted-by":"publisher","first-page":"727117","DOI":"10.3389\/fpsyt.2021.727117","volume":"12","author":"MV Vargas","year":"2021","unstructured":"Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE. Psychedelics and Other Psychoplastogens for Treating Mental Illness. Front Psychiatry. 2021;12:727117. https:\/\/doi.org\/10.3389\/fpsyt.2021.727117.","journal-title":"Front Psychiatry"},{"key":"1069_CR5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2022."},{"issue":"2","key":"1069_CR6","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1016\/j.cub.2021.12.009","volume":"32","author":"B Kelmendi","year":"2022","unstructured":"Kelmendi B, Kaye AP, Pittenger C, Kwan AC, Psychedelics. Curr Biol. 2022;32(2):R63\u20137. https:\/\/doi.org\/10.1016\/j.cub.2021.12.009.","journal-title":"Curr Biol"},{"key":"1069_CR7","volume-title":"The Psychedelic Handbook. A practical guide to Psilocybin, LSD, Ketamine, MDMA, and DMT\/Ayahuasca","author":"R Strassman","year":"2022","unstructured":"Strassman R. The Psychedelic Handbook. A practical guide to Psilocybin, LSD, Ketamine, MDMA, and DMT\/Ayahuasca. Berkeley, CA: Ulysses; 2022."},{"issue":"4","key":"1069_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.31887\/DCNS.2007.9.4\/macrocq","volume":"9","author":"MA Crocq","year":"2007","unstructured":"Crocq MA. Historical and cultural aspects of man\u2019s relationship with addictive drugs. Rev Dialogues Clin Neurosci. 2007;9(4):355\u201361.","journal-title":"Rev Dialogues Clin Neurosci"},{"key":"1069_CR9","unstructured":"Dixon Olard. The mystery of Amanita Muscaria. \u041e\u043b\u0430\u0440\u0434 \u0414\u0438\u043a\u0441\u043e\u043d. \u041c\u0438\u0441\u0442\u0435\u0440\u0438\u0438 \u041c\u0443\u0445\u043e\u043c\u043e\u0440\u0430. Hartola, Finland, Treemedia Content Oy. 2021. 397 pp."},{"key":"1069_CR10","doi-asserted-by":"publisher","DOI":"10.1556\/2054.2019.008","author":"G Samorini","year":"2019","unstructured":"Samorini G. The oldest archeological data evidencing the relationship of Homo sapiens with psychoactive plants: a worldwide overview. J Psychedelic Stud. 2019. https:\/\/doi.org\/10.1556\/2054.2019.008.","journal-title":"J Psychedelic Stud"},{"issue":"23","key":"1069_CR11","doi-asserted-by":"publisher","first-page":"11207","DOI":"10.1073\/pnas.1902174116","volume":"116","author":"MJ Miller","year":"2019","unstructured":"Miller MJ, Albarracin-Jordan J, Moore C, Capriles JM. Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America. PNAS. 2019;116(23):11207\u201312. https:\/\/doi.org\/10.1073\/pnas.1902174116.","journal-title":"PNAS"},{"issue":"8","key":"1069_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jama.2025.10978","volume":"334","author":"S Anderer","year":"2025","unstructured":"Anderer S. Esketamine Monotherapy Effective for Treatment-Resistant Depression. JAMA. 2025;334(8):661\u20132. https:\/\/doi.org\/10.1001\/jama.2025.10978.","journal-title":"JAMA"},{"issue":"9","key":"1069_CR13","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1001\/jamapsychiatry.2025.1317","volume":"82","author":"A Janik","year":"2025","unstructured":"Janik A, Qiu X, Lane R, et al. Esketamine monotherapy in adults with treatment-resistant depression. a randomized clinical trial. JAMA Psychiatry. 2025;82(9):877\u201387. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.1317.","journal-title":"JAMA Psychiatry"},{"key":"1069_CR14","unstructured":"https:\/\/www.tga.gov.au\/news\/media-releases\/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists Accessed on December 27, 2025."},{"issue":"21","key":"1069_CR15","doi-asserted-by":"publisher","first-page":"8174","DOI":"10.1073\/pnas.0402680101","volume":"101","author":"N Gogtay","year":"2004","unstructured":"Gogtay N, Giedd JN, Lusk L, Hayashi KM, Greenstein D, et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A. 2004;101(21):8174\u20139. https:\/\/doi.org\/10.1073\/pnas.0402680101.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1069_CR16","doi-asserted-by":"publisher","unstructured":"Izmi N, Carhart-Harris RL, Kettner H. Psychological effects of psychedelics in adolescents. Front Child Adolesc Psychiatry. 2024;3(1364617). https:\/\/doi.org\/10.3389\/frcha.2024.1364617.","DOI":"10.3389\/frcha.2024.1364617"},{"issue":"2","key":"1069_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41591-025-04194-5","volume":"32","author":"JS Siegel","year":"2026","unstructured":"Siegel JS, Liston C, Nicol GE, Carhart-Harris RL, Bogenschutz MP. The science of psychedelic medicine. Nat Med. 2026;32(2):449\u201362. https:\/\/doi.org\/10.1038\/s41591-025-04194-5. Epub 2026 Feb 6. PMID: 41652120.","journal-title":"Nat Med"},{"key":"1069_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S2215-0366(23)00345-0","volume":"11","author":"S Cortese","year":"2024","unstructured":"Cortese S, Purper-Ouakil D, Apter A, Arango C, Baeza I, et al. Psychopharmacology in children and adolescents: unmet needs and opportunities. Lancet Psychiatry. 2024;11:143\u201354. https:\/\/doi.org\/10.1016\/S2215-0366(23)00345-0.","journal-title":"Lancet Psychiatry"},{"key":"1069_CR19","doi-asserted-by":"publisher","unstructured":"Jeffrey JK, Weintraub MJ, Grob CS. Clinical research trials of psychedelic-assisted therapy in adolescents aged 16 to 17 years: rationale balanced with caution. J Am Acad Child Adolesc Psychiatry. 2024. https:\/\/doi.org\/10.1016\/j.jaac.2024.03.021","DOI":"10.1016\/j.jaac.2024.03.021"},{"issue":"12","key":"1069_CR20","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2024.2546","volume":"81","author":"JT Hinkle","year":"2024","unstructured":"Hinkle JT, Graziosi M, Nayak SM, Yaden D. Adverse events in studies of classic psychedelics. A systematic review and meta-analysis. JAMA Psychiatry. 2024;81(12):1225\u201335. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.2546. Published online September 4, 2024.","journal-title":"JAMA Psychiatry"},{"key":"1069_CR21","first-page":"21","volume":"118","author":"EM Ornitz","year":"1973","unstructured":"Ornitz EM. Childhood autism: A review of the clinical and experimental literature (Medical Progress). Calif Med. 1973;118:21\u201347. Apr.","journal-title":"Calif Med"},{"key":"1069_CR22","doi-asserted-by":"crossref","unstructured":"Rajwani K, Jacobs E, Bruce L, Hokanson J, Almonte MT, Feroz F. Clinical psychedelic research in adolescents: a scoping review and overview of ethical considerations. Lancet. Child Adolesc Health. Review. 2025;9(10),744-75210.1016\/S2352-4642(25)00208-1.","DOI":"10.1016\/S2352-4642(25)00208-1"},{"issue":"1","key":"1069_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaac.2025.02.015","volume":"65","author":"C Kosik-Gonzalez","year":"2026","unstructured":"Kosik-Gonzalez C, Fu DJ, Chen LN, Lane R, Bloch MH, DelBello M, Moreno C, Drevets WC, Canuso CM. Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study. J Am Acad Child Adolesc Psychiatry. 2026;65(1):42\u201355.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1069_CR24","unstructured":"https:\/\/blossomanalysis.com\/trials\/?_trials_topic=63607 Accessed on 6 December 2025."},{"issue":"3","key":"1069_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1176\/appi.focus.24022013","volume":"22","author":"S Knatz Peck","year":"2024","unstructured":"Knatz Peck S, Shao S, Gruen T, Yang K, Babakanian A, Trim J, Finn DM, Kaye WH. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Focus (Am Psychiatr Publ). 2024;22(3):381\u20137. https:\/\/doi.org\/10.1176\/appi.focus.24022013. Epub 2024 Jun 28.","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"1069_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/ijnp\/pyae057","volume":"27","author":"HM Collins","year":"2024","unstructured":"Collins HM. Psychedelics for the treatment of obsessive\u2013compulsive disorder: efficacy and proposed mechanisms. Rev Int J Neuropsychopharmacol. 2024;27:12. https:\/\/doi.org\/10.1093\/ijnp\/pyae057.","journal-title":"Rev Int J Neuropsychopharmacol"},{"key":"1069_CR27","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","volume":"235","author":"AL Danforth","year":"2018","unstructured":"Danforth AL, Grob2 CS, Struble C, Feduccia AA, Walker N, Jerome L, Yazar-Klosinski B, Emerson A. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology. 2018;235:3137\u201348. https:\/\/doi.org\/10.1007\/s00213-018-5010-9.","journal-title":"Psychopharmacology"},{"key":"1069_CR28","doi-asserted-by":"publisher","unstructured":"Agnorelli C, Spriggs M, Godfrey K, Sawicka G, Bohl B, Douglass H, Fagiolini A, Parastoo H, Carhart-Harris R, Nutt D, Erritzoe D. Neuroplasticity and psychedelics: a comprehensive examination of classic and non-classic compounds in pre- and clinical models. Neurosci Biobehav Rev. 2025;172:106132. https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106132.\u00a0","DOI":"10.1016\/j.neubiorev.2025.106132"},{"key":"1069_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","volume":"1","author":"F Holze","year":"2023","unstructured":"Holze F, Gasser P, M\u00fcller F, Dolder PC, Liechti ME. Lysergic acid diethylamide\u2013assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase 2 study. Biol Psychiatry Febr. 2023;1:93:215\u201323. https:\/\/doi.org\/10.1016\/j.biopsych.2022.08.025.","journal-title":"Biol Psychiatry Febr"},{"key":"1069_CR30","doi-asserted-by":"publisher","unstructured":"Hatzipantelis CJ, Olson DE. The effects of psychedelics on neuronal physiology. Annu Rev Physiol 2024 Febr 12; 86: 27\u201347. https:\/\/doi.org\/10.1146\/annurev-physiol-042022-020923","DOI":"10.1146\/annurev-physiol-042022-020923"},{"issue":"6","key":"1069_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1001\/jamapsychiatry.2024.0","volume":"81","author":"O Simonsson","year":"2024","unstructured":"Simonsson O, Mosing MA, Osika W, et al. Adolescent Psychedelic Use and Psychotic or Manic Symptoms. JAMA Psychiatry. 2024;81(6):579\u201385. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0.","journal-title":"JAMA Psychiatry"},{"key":"1069_CR32","unstructured":"FDA Guidance Document. Psychedelic drugs: considerations for clinical investigations. Guidance for Industry. 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/psychedelic-drugs-considerations-clinical-investigations Accessed on 24 February 2026."}],"container-title":["Child and Adolescent Psychiatry and Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13034-026-01069-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13034-026-01069-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13034-026-01069-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T02:37:17Z","timestamp":1776739037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13034-026-01069-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1069"],"URL":"https:\/\/doi.org\/10.1186\/s13034-026-01069-6","relation":{},"ISSN":["1753-2000"],"issn-type":[{"value":"1753-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"11 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}